Electroporation-based technologies for medicine: Principles, applications, and challenges

Annual Review of Biomedical Engineering

Volumn 16, Issue , 2014, Pages 295-320

  Yarmush, Martin L ^a,b   Golberg, Alexander ^a   Serša, Gregor ^c   Kotnik, Tadej ^d   Miklavčič, Damijan ^d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c INSTITUTE OF ONCOLOGY   (Slovenia)

^d UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

DNA vaccination; electrochemotherapy; electropermeabilization; gene electrotransfer; irreversible electroporation; Pulsed electric field

Indexed keywords

CELL MEMBRANES; CYTOLOGY; TISSUE;

DNA VACCINATION; ELECTROCHEMOTHERAPY; ELECTROPERMEABILIZATION; ELECTROPORATION; ELECTROTRANSFER; PULSED ELECTRIC FIELD;

ELECTRIC FIELD EFFECTS;

CHANNEL GATING; COMPUTER ASSISTED TOMOGRAPHY; DNA IMMUNIZATION; ELECTROCHEMOTHERAPY; ELECTROPORATION; IMPEDANCE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PULSED ELECTRIC FIELD; REVIEW; THERMAL INJURY; ULTRASOUND; ANIMAL; BIOMEDICAL ENGINEERING; CELL MEMBRANE; CELL MEMBRANE PERMEABILITY; DRUG DELIVERY SYSTEM; ECHOGRAPHY; ELECTROMAGNETIC FIELD; HUMAN; INTRADERMAL DRUG ADMINISTRATION; METABOLISM; METASTASIS; NEOPLASMS; PERMEABILITY; PHYSIOLOGY; PROCEDURES; THERMODYNAMICS; TISSUE ENGINEERING;

SMALL INTERFERING RNA;

ADMINISTRATION, CUTANEOUS; ANIMALS; BIOMEDICAL ENGINEERING; CELL MEMBRANE; CELL MEMBRANE PERMEABILITY; DRUG DELIVERY SYSTEMS; ELECTRIC IMPEDANCE; ELECTROCHEMOTHERAPY; ELECTROMAGNETIC FIELDS; ELECTROPORATION; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; PERMEABILITY; POSITRON-EMISSION TOMOGRAPHY; RNA, SMALL INTERFERING; THERMODYNAMICS; TISSUE ENGINEERING; TOMOGRAPHY, X-RAY COMPUTED; ULTRASONOGRAPHY;

EID: 84904351599     PISSN: 15239829     EISSN: 15454274     Source Type: Book Series    
DOI: 10.1146/annurev-bioeng-071813-104622     Document Type: Review

References (184)

1. Miklavcic D. 2012. Network for development of electroporation-based technologies and treatments: COST TD1104.J. Membr. Biol. 245:591-98
2. Nollet JA. 1754. Recherches sur les causes particulieres des phénoménes électriques. Paris: Guerin & Delatour
3. Noad HM. 1849. Lectures on Electricity: Comprising Galvinism, Magnetism, Electromagnetism, Magneto-and Thermo-Electricity, and Electro-Physiology. London: Knight. 3rd ed.
4. Frankenhaeuser B, Widen L. 1956. Anode break excitation in desheathed frog nerve. J. Physiol. 131:243-47
5. Stampfli R, Willi M. 1957. Membrane potential of a Ranvier node measured after electrical destruction of its membrane. Experientia 13:297-98
6. Neumann E, Schaefer-Ridder M, Wang Y, Hofschneider PH. 1982. Gene transfer into mouse lyoma cells by electroporation in high electric fields. EMBOJ. 1:841-45
7. Mir LM, Belehradek M, Domenge C, Orlowski S, Poddevin B, et al. 1991. [Electrochemotherapy, a new antitumor treatment: first clinical trial]. C. R. Acad. Sci. III 313:613-18
8. Okino M, Mohri H. 1987. Effects of a high-voltage electrical impulse and an anticancer drug on in vivo growing tumors. Jpn. J. CancerRes. Gann 78:1319-21
9. Orlowski S, Belehradek J Jr, Paoletti C, Mir LM. 1988. Transient electropermeabilization of cells in culture: increase of the cytotoxicity of anticancer drugs. Biochem. Pharmacol. 37:4727-33
10. Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, et al. 2008. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J. Clin. Oncol. 26:5896-903
11. Titomirov AV, Sukharev S, Kistanova E. 1991. In vivo electroporation and stable transformation of skin cells of newborn mice by plasmid DNA. Biochim. Biophys. Acta 1088:131-34
12. Davalos R, Mir LM, Rubinsky B. 2005. Tissue ablation with irreversible electroporation. Ann. Biomed. Eng. 33:223-31
13. Golberg A, Yarmush ML. 2013. Nonthermal irreversible electroporation: fundamentals, applications, and challenges. IEEE Trans. Biomed. Eng. 60:707-14
14. Michael DH, O'Neill ME. 1970. Electrohydrodynamic instability in plane layers of fluid. J. Fluid Mech. 41:571-80
15. Crowley JM. 1973. Electrical breakdown of bimolecular lipid membranes as an electromechanical instability. Biophys. J. 13:711-24
16. Steinchen A, Gallez D, Sanfeld A. 1982. A viscoelastic approach to the hydrodynamic stability of membranes. J. Colloid Interface Sci. 85:5-15
17. Sugar IP. 1979. A theory of the electric field-induced phase transition of phospholipid bilayers. Biochim. Biophys. Acta 556:72-85
18. Cruzeiro-Hansson L, Mouritsen OG. 1988. Passive ion permeability of lipid membranes modelled via lipid-domain interfacial area. Biochim. Biophys. Acta 944:63-72
19. Tsong TY. 1991. Electroporation of cell membranes. Biophys. J. 60:297-306
20. Weaver JC, Chizmadzhev YA. 1996. Theory of electroporation: a review. Bioelectrochem. Bioenerg. 41:135-60
21. Spugnini EP, Arancia G, Porrello A, Colone M, Formisano G, et al. 2007. Ultrastructural modifications of cell membranes induced by electroporation on melanoma xenografts. Microsc. Res. Tech. 70:1041-50
22. Freeman SA, Wang MA, Weaver JC. 1994. Theory of electroporation of planar bilayer membranes: predictions of the aqueous area, change in capacitance, and pore-pore separation. Biophys. J. 67:42-56
23. Kotnik T, Kramar P, Pucihar G, Miklavčič D, Tarek M. 2012. Cell membrane electroporation-part 1: the phenomenon. IEEE Electrical Insulation Mag. 28:14-23
24. Schoenbach K, Beebe S, Buescher E. 2001. Intracellular effect of ultrashort electrical pulses. Bioelectro-magnetics 22:440-48
25. Kotnik T, Miklavčič D. 2006. Theoretical evaluation of voltage inducement on internal membranes of biological cells exposed to electric fields. Biophys. J. 90:480-91
26. Delemotte L, Tarek M. 2012. Molecular dynamics simulations of lipid membrane electroporation. J. Membr. Biol. 245:531-43
27. Gimsa J, Wachner D. 2001. Analytical description of the transmembrane voltage induced on arbitrarily oriented ellipsoidal and cylindrical cells. Biophys. J. 81:1888-96
28. Kotnik T, Bobanović F, Miklavčič D. 1997. Sensitivity of transmembrane voltage induced by applied electric fields- A theoretical analysis. Bioelectrochem. Bioenerg. 43:285-91
29. Kotnik T, Miklavčič D. 2000. Analytical description of transmembrane voltage induced by electric fields on spheroidal cells. Biophys. J. 79:670-79
30. Kotnik T, Miklavčič D. 2000. Second-order model of membrane electric field induced by alternating external electric fields. IEEE Trans. Biomed. Eng. 47:1074-81
31. Kotnik T, Miklavčič D, Slivnik T. 1998. Time course of transmembrane voltage induced by time-varying electric fields- A method for theoretical analysis and its application. Bioelectrochem. Bioenerg. 45:3-16
32. Pucihar G, Kotnik T, Valič B, Miklavčič D. 2006. Numerical determination of transmembrane voltage induced on irregularly shaped cells. Ann. Biomed. Eng. 34:642-52
33. Ying WJ, Henriquez CS. 2007. Hybrid finite element method for describing the electrical response of biological cells to applied fields. IEEE Trans. Biomed. Eng. 54:611-20
34. Pucihar G, Miklavčič D, Kotnik T. 2009. A time-dependent numerical model of transmembrane voltage inducement and electroporation of irregularly shaped cells. IEEE Trans. Biomed. Eng. 56:1491-501
35. Loew LM. 1992. Voltage sensitive dyes: measurement of membrane potentials induced by DC and AC electric fields. Bioelectromagnetics 13:179-89
36. Pucihar G, Kotnik T, Miklavčič D. 2009. Measuring the induced membrane voltage with di-8-ANEPPS. J. Visualized Exp. 33:1659
37. Kotnik T, Pucihar G, Miklavčič D. 2010. Induced transmembrane voltage and its correlation with electroporation-mediated molecular transport. J. Membr. Biol. 236:3-13
38. Saulis G, Venslauskas MS, Naktinis J. 1991. Kinetics of pore resealing in cell membranes after electro-poration. Bioelectrochem. Bioenerg. 26:1-13
39. Hibino M, Itoh H, Kinosita K. 1993. Time courses of cell electroporation as revealed by submicrosecond imaging of transmembrane potential. Biophys. J. 64:1789-800
40. Pucihar G, Kotnik T, Miklavčič D, Teissié J. 2008. Kinetics of transmembrane transport of small molecules into electropermeabilized cells. Biophys. J. 95:2837-48
41. Paganin-Gioanni A, Bellard E, Escoffre JM, Rols MP, Teissié J, Golzio M. 2011. Direct visualization at the single-cell level of siRNA electrotransfer into cancer cells. Proc. Natl. Acad. Sci. USA 108:10443-47
42. Golzio M, Teissié J, Rols M-P. 2002. Direct visualization at the single-cell level of electrically mediated gene delivery. Proc. Natl. Acad. Sci. USA 99:1292-97
43. Testori A, Tosti G, Martinoli C, Spadola G, Cataldo F, et al. 2010. Electrochemotherapy for cutaneous and subcutaneous tumor lesions: a novel therapeutic approach. Dermatol. Ther. 23:651-61
44. Cemažar M, Tamzali Y, Serša G, Tozon N, Mir LM, et al. 2008. Electrochemotherapy in veterinary oncology. J. Vet. Intern. Med. 22:826-31
45. Miklavčič D, Serša G, Brecelj E, Gehl J, Soden D, et al. 2012. Electrochemotherapy: technological advancements for efficient electroporation-based treatment of internal tumors. Med. Biol. Eng. Comput. 50:1213-25
46. Mir LM, Orlowski S, Belehradek J Jr, Paoletti C. 1991. Electrochemotherapy potentiation of antitumour effect of bleomycin by local electric pulses. Eur. J. Cancer 27:68-72
47. Serša G, Cemažar M, Miklavčič D. 1995. Antitumor effectiveness of electrochemotherapy with cis- diamminedichloroplatinum(II) in mice. Cancer Res. 55:3450-55
48. Gehl J, Skovsgaard T, Mir LM. 1998. Enhancement of cytotoxicity by electropermeabilization: an improved method for screening drugs. Anticancer Drugs 9:319-25
49. Gehl J. 2003. Electroporation: theory and methods, perspectives for drug delivery, gene therapy and research. Acta Physiol. Scand. 177:437-47
50. Cemažar M, Miklavčič D, Sčančar J, Dolžan V, Golouh R, Serša G. 1999. Increased platinum accumulation in SA-1 tumour cells after in vivo electrochemotherapy with cisplatin. Br. J. Cancer 79:1386-91
51. Bellard E, Markelc B, Pelofy S, Le Guerroue F, Serša G, et al. 2012. Intravital microscopy at the single vessel level brings new insights of vascular modification mechanisms induced by electropermeabilization. J. Control. Release 163:396-403
52. Edhemović I, Gadžijev EM, Brecelj E, Miklavč ič D, Kos B, et al. 2011. Electrochemotherapy: a new technological approach in treatment of metastases in the liver. Technol. Cancer Res. Treat. 10:475-85
53. Jarm T, Cemažar M, Miklavčič D, Serša G. 2010. Antivascular effects of electrochemotherapy: implications in treatment of bleeding metastases. Expert Rev. Anticancer Ther. 10:729-46
54. Markelc B, Serša G, Cemažar M. 2013. Differential mechanisms associated with vascular disrupting action of electrochemotherapy: intravital microscopy on the level of single normal and tumor blood vessels. PLoS ONE 8:e59557
55. Serša G, Jarm T, Kotnik T, Coer A, Podkrajšek M, et al. 2008. Vascular disrupting action of electropo-ration and electrochemotherapy with bleomycin in murine sarcoma. Br. J. Cancer 98:388-98
56. Roux S, Bernat C, Al-Sakere B, Ghiringhelli F, Opolon P, et al. 2008. Tumor destruction using elec-trochemotherapy followed by CpG oligodeoxynucleotide injection induces distant tumor responses. Cancer Immunol. Immunother. 57:1291-300
57. Sedlar A, Dolinšek T, Markelc B, Prosen L, Kranjc S, et al. 2012. Potentiation of electrochemotherapy by intramuscular IL-12 gene electrotransfer in murine sarcoma and carcinoma with different immuno-genicity. Radiol. Oncol. 46:302-11
58. Serša G, Miklavčič D, Cemažar M, Belehradek J, Jarm T, Mir LM. 1997. Electrochemotherapy with CDDP on LPB sarcoma: comparison of the anti-tumor effectiveness in immunocompetent and immu-nodeficient mice. Bioelectrochem. Bioenerg. 43:279-83
59. Heller L, Pottinger C, Jaroszeski MJ, Gilbert R, Heller R. 2000. In vivo electroporation of plasmids encoding GM-CSF or interleukin-2 into existing B16 melanomas combined with electrochemotherapy induces long-term antitumour immunity. Melanoma Res. 10:577-83
60. Serša G, Cemažar M, Menart V, Gaberc-Porekar V, Miklavčič D. 1997. Anti-tumor effectiveness of electrochemotherapy with bleomycin is increased by TNF-α on SA-1 tumors in mice. Cancer Lett. 116:85-92
61. Torrero MN, Henk WG, Li S. 2006. Regression of high-grade malignancy in mice by bleomycin and interleukin-12 electrochemogenetherapy. Clin. Cancer Res. 12:257-63
62. Mir LM, Orlowski S, Poddevin B, Belehradek J Jr. 1992. Electrochemotherapy tumor treatment is improved by interleukin-2 stimulation of the host's defenses. Eur. Cytokine Netw. 3:331-34
63. Heller R. 1995. Treatment of cutaneous nodules using electrochemotherapy. J. Fla. Med. Assoc. 82:147-50
64. Serša G, Stabuc B, Cemažar M, Miklavčič D, Rudolf Z. 2000. Electrochemotherapy with cisplatin: clinical experience in malignant melanoma patients. Clin. Cancer Res. 6:863-67
65. Mir LM, Glass LF, Serša G, Teissié J, Domenge C, et al. 1998. Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy. Br. J. Cancer 77:2336-42
66. Marty M, Serša G, Garbay JR, Gehl J, Collins CG, et al. 2006. Electrochemotherapy-an easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study. Eur. J. Cancer Suppl. 4:3-13
67. TM by means of invasive or non-invasive electrodes. Eur. J. Cancer Suppl. 4:14-25
68. Serša G, Miklavčič D, Cemažar M, Rudolf Z, Pucihar G, Snoj M. 2008. Electrochemotherapy in treatment of tumours. Eur. J. Surg. Oncol. 34:232-40
69. Mali B, Jarm T, Snoj M, Serša G, Miklavčič D. 2013. Antitumor effectiveness of electrochemotherapy: a systematic review and meta-analysis. Eur. J. Surg. Oncol. 39:4-16
70. Campana LG, Mocellin S, Basso M, Puccetti O, De Salvo GL, et al. 2009. Bleomycin-based electrochemotherapy: clinical outcome from a single institution's experience with 52 patients. Ann. Surg. Oncol. 16:191-99
71. Mali B, Miklavčič D, Campana LG, Cemažar M, Serša G, et al. 2013. Tumor size and effectiveness of electrochemotherapy. Radiol. Oncol. 47:32-41
72. Serša G, Cufer T, Paulin SM, Cemažar M, Snoj M. 2012. Electrochemotherapy of chest wall breast cancer recurrence. Cancer Treat. Rev. 38:379-86
73. Campana LG, Valpione S, Falci C, Mocellin S, Basso M, et al. 2012. The activity and safety of elec-trochemotherapy in persistent chest wall recurrence from breast cancer after mastectomy: a Phase-II study. Breast Cancer Res. Treat. 134:1169-78
74. Matthiessen LW, Johannesen HH, Hendel HW, Moss T, Kamby C, Gehl J. 2012. Electrochemotherapy for large cutaneous recurrence of breast cancer: a Phase II clinical trial. Acta Oncol. 51:713-21
75. Gargiulo M, Papa A, Capasso P, Moio M, Cubicciotti E, Parascandolo S. 2012. Electrochemotherapy for non-melanoma head and neck cancers: clinical outcomes in 25 patients. Ann. Surg. 255:1158-64
76. Testori A, Faries MB, Thompson JF, Pennacchioli E, Deroose JP, et al. 2011. Local and intralesional therapy of in-transit melanoma metastases. J. Surg. Oncol. 104:391-96
77. Kodre V, Cemažar M, Pečar J, Serša G, Cor A, Tozon N. 2009. Electrochemotherapy compared to surgery for treatment of canine mast cell tumours. In Vivo 23:55-62
78. Mir LM, Devauchelle P, Quintin-Colonna F, Delisle F, Doliger S, et al. 1997. First clinical trial of cat soft-tissue sarcomas treatment by electrochemotherapy. Br. J. Cancer 76:1617-22
79. Rols MP, Tamzali Y, Teissié J. 2002. Electrochemotherapy of horses: a preliminary clinical report. Bioelectrochemistry 55:101-5
80. Spugnini EP, Vincenzi B, Citro G, Dotsinsky I, Mudrov T, Baldi A. 2011. Evaluation of cisplatin as an electrochemotherapy agent for the treatment of incompletely excised mast cell tumors in dogs. J. Vet. Intern. Med. 25:407-11
81. Tamzali Y, Borde L, Rols MP, Golzio M, Lyazrhi F, Teissié J. 2012. Successful treatment of equine sarcoids with cisplatin electrochemotherapy: a retrospective study of 48 cases. Equine Vet. J. 44:214-20
82. Tozon N, Serša G, Cemažar M. 2001. Electrochemotherapy: potentiation of local antitumour effectiveness of cisplatin in dogs and cats. Anticancer Res. 21:2483-88
83. Maor E, Ivorra A, Leor J, Rubinsky B. 2007. The effect of irreversible electroporation on blood vessels. Technol. Cancer Res. Treat. 6:307-12
84. Phillips MA, Narayan R, Padath T, Rubinsky B. 2012. Irreversible electroporation on the small intestine. Br. J. Cancer 106:490-95
85. Lee EW, Chen C, Prieto VE, Dry SM, Loh CT, Kee ST. 2010. Advanced hepatic ablation technique for creating complete cell death: irreversible electroporation. Radiology 255:426-33
86. Golberg A, Broelsch G, Bohr S, Mihm M, Austen W, et al. 2013. Non-thermal, pulsed electric field cell ablation: a novel tool for regenerative medicine and scarless skin regeneration. Technology 1:1-8
87. Miller L, Leor J, Rubinsky B. 2005. Cancer cells ablation with irreversible electroporation. Technol. Cancer Res. Treat. 4:699-705
88. Edd JF, Horowitz L, Davalos RV, Mir LM, Rubinsky B. 2006. In vivo results of a new focal tissue ablation technique: irreversible electroporation. IEEE Trans. Biomed. Eng. 53:1409-15
89. Rubinsky B, Onik G, Mikus P. 2007. Irreversible electroporation: a new ablation modality-clinical implications. Technol. Cancer Res. Treat. 6:37-48
90. Martin RCG, McFarland K, Ellis S, Velanovich V. 2012. Irreversible electroporation therapy in the management of locally advanced pancreatic adenocarcinoma. J. Am. Coll. Surg. 215:361-69
91. Onik G, Rubinsky B. 2010. Irreversible electroporation: first patient experience focal therapy of prostate cancer. In Irreversible Electroporation, ed. B Rubinsky, pp. 235-47. Berlin: Springer
92. Guo Y, Zhang Y, Klein R, Nijm GM, Sahakian AV, et al. 2010. Irreversible electroporation therapy in the liver: longitudinal efficacy studies in a rat model of hepatocellular carcinoma. Cancer Res. 70:1555-63
93. José A, Sobrevals L, Ivorra A, Fillat C. 2012. Irreversible electroporation shows efficacy against pancreatic carcinoma without systemic toxicity in mouse models. Cancer Lett. 317:16-23
94. Golberg A, Bei M, Sheridan R, Yarmush M. 2013. Regeneration and control of human fibroblast cell density by intermittently delivered pulsed electric fields. Biotechnol. Bioeng. 110:1759-68
95. Golberg A, Rubinsky B. 2010. A statistical model for multidimensional irreversible electroporation cell death in tissue. Biomed. Eng. OnLine 9:13
96. Al-Sakere B, Bernat C, André F, Connault E, Opolon P, et al. 2007. A study of the immunological response to tumor ablation with irreversible electroporation. Technol. Cancer Res. Treat. 6:301-5
97. Onik G, Mikus P, Rubinsky B. 2007. Irreversible electroporation: implications for prostate ablation. Technol. Cancer Res. Treat. 6:295-300
98. Neal RE II, Rossmeisl JH Jr, Robertson JL, Arena CB, Davis EM, et al. 2013. Improved local and systemic anti-tumor efficacy for irreversible electroporation in immunocompetent versus immunodeficient mice. PLoS ONE 8:e64559
99. Bagla S, Papadouris D. 2012. Percutaneous irreversible electroporation of surgically unresectable pancreatic cancer: a case report. J. Vasc. Interv. Radiol. 23:142-45
100. Pech M, Janitzky A, Wendler JJ, Strang C, Blaschke S, et al. 2011. Irreversible electroporation of renal cell carcinoma: a first-in-man Phase I clinical study. Cardiovasc. Interv. Radiol. 34:132-38
101. Thomson KR, Cheung W, Ellis SJ, Federman D, Kavnoudias H, et al. 2011. Investigation of the safety of irreversible electroporation in humans. J. Vasc. Interv. Radiol. 22:611-21
102. Usman M, Moore W, Talati R, Watkins K, Bilfinger TV. 2012. Irreversible electroporation of lung neoplasm: a case series. Med. Sci. Monit. 18:CS43-47
103. Bruix J, Izzo F, Crocetti L, Vilgrain V, Abdel-Rehim M, et al. 2012. Irreversible electroporation for the treatment of early-stage hepatocellular carcinoma: a prospective multicenter Phase 2 study assessing safety and efficacy. J. Hepatol. 56(Suppl. 2):S554
104. Kingham TP, Karkar AM, D'Angelica MI, Allen PJ, DeMatteo RP, et al. 2012. Ablation of perivascular hepatic malignant tumors with irreversible electroporation. J. Am. Coll. Surg. 215:379-87
105. Ball C, Thomson KR, Kavnoudias H. 2010. Irreversible electroporation: a new challenge in "out of operating theater" anesthesia. Anesth. Analg. 110:1305-9
106. Akinwande O, Samman M. 2013. Irreversible electroporation: hype or hope? Cardiovasc. Interv. Radiol. 36:1719-20
107. Garcia PA, Pancotto T, Rossmeisl JH Jr, Henao-Guerrero N, Gustafson NR, et al. 2011. Non-thermal irreversible electroporation (N-TIRE) and adjuvant fractionated radiotherapeutic multimodal therapy for intracranial malignant glioma in a canine patient. Technol. Cancer Res. Treat. 10:73-83
108. Neal RE, Rossmeisl JH, Garcia PA, Lanz OI, Henao-Guerrero N, Davalos RV. 2011. Successful treatment of a large soft tissue sarcoma with irreversible electroporation. J. Clin. Oncol. 29:e372-77
109. Ellis TL, Garcia PA, Rossmeisl JH Jr, Henao-Guerrero N, Robertson J, Davalos RV. 2011. Nonthermal irreversible electroporation for intracranial surgical applications: laboratory investigation. J. Neurosurg. 114:681-88
110. Heller LC, Heller R. 2010. Electroporation gene therapy preclinical and clinical trials for melanoma. Curr. Gene Ther. 10:312-17
111. Cemažar M, Jarm T, Serša G. 2010. Cancer electrogene therapy with interleukin-12. Curr. Gene Ther. 10:300-11
112. Zhao Y, Moon E, Carpenito C, Paulos CM, Liu X, et al. 2010. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res. 70:9053-61
113. Sardesai NY, Weiner DB. 2011. Electroporation delivery of DNA vaccines: prospects for success. Curr. Opin. Immunol. 23:421-29
114. Rols MP, Delteil C, Golzio M, Dumond P, Cros S, Teissié J. 1998. In vivo electrically mediated protein and gene transfer in murine melanoma. Nat. Biotechnol. 16:168-71
115. Heller R, Jaroszeski M, Atkin A, Moradpour D, Gilbert R, et al. 1996. In vivo gene electroinjection and expression in rat liver. FEBS Lett. 389:225-28
116. Aihara H, Miyazaki J. 1998. Gene transfer into muscle by electroporation in vivo. Nat. Biotechnol. 16:867-70
117. Heller LC, Heller R. 2006. In vivo electroporation for gene therapy. Hum. Gene Ther. 17:890-97
118. Favard C, Dean DS, Rols MP. 2007. Electrotransfer as a non viral method of gene delivery. Curr. Gene Ther. 7:67-77
119. Cemažar M, Serša G. 2007. Electrotransfer of therapeutic molecules into tissues. Curr. Opin. Mol. Ther. 9:554-62
120. André F, Gehl J, Serša G, Préat V, Hojman P, et al. 2008. Efficiency of high-and low-voltage pulse combinations for gene electrotransfer in muscle, liver, tumor, and skin. Hum. Gene Ther. 19:1261-71
121. Martel-Renoir D, Trochon-Joseph V, Galaup A, Bouquet C, Griscelli F, et al. 2003. Coelectrotransfer to skeletal muscle of three plasmids coding for antiangiogenic factors and regulatory factors of the tetracycline-inducible system: tightly regulated expression, inhibition of transplanted tumor growth, and antimetastatic effect. Mol. Ther. 8:425-33
122. Jazowiecka-Rakus J, Jarosz M, Szala S. 2006. Combination of vasostatin gene therapy with cyclophos-phamide inhibits growth of B16(F10) melanoma tumours. Acta Biochim. Pol. 53:199-202
123. Cichon T, Jamrozy L, Glogowska J, Missol-Kolka E, Szala S. 2002. Electrotransfer of gene encoding endostatin into normal and neoplastic mouse tissues: inhibition of primary tumor growth and metastatic spread. Cancer Gene Ther. 9:771-77
124. Tao J, Tu YT, Huang CZ, Feng AP, Wu Q, et al. 2005. Inhibiting the growth of malignant melanoma by blocking the expression of vascular endothelial growth factor using an RNA interference approach. Br. J. Dermatol. 153:715-24
125. Bošnjak M, Prosen L, Dolinšek T, Blagus T, Markelc B, et al. 2013. Biological properties of melanoma and endothelial cells after plasmid AMEP gene electrotransfer depend on integrin quantity on cells. J. Membr. Biol. 246:803-19
126. Dolinšek T, Markelc B, Serša G, Coer A, Stimac M, et al. 2013. Multiple delivery of siRNA against endoglin into murine mammary adenocarcinoma prevents angiogenesis and delays tumor growth. PLoS ONE 8:e58723
127. Spanggaard I, Snoj M, Cavalcanti A, Bouquet C, Serša G, et al. 2013. Gene electrotransfer of plasmid antiangiogenic metargidin peptide (AMEP) in disseminated melanoma: safety and efficacy results of a Phase I first-in-man study. Hum. Gene Ther. Clin. Dev. 24(3):99-107
128. Pavlin D, Cemažar M, Serša G, Tozon N. 2012. IL-12 based gene therapy in veterinary medicine. J. Transl. Med. 10:234
129. Tamzali Y, Couderc B, Rols MP, Golzio M, Teissié J. 2007. Equine cutaneous tumors treatment by electro-chemo-immuno-geno-therapy. In 11th Mediterr. Conf. Med. Biomed. Eng. Comput. 2007 Proc., ed. T Jarm, P Kramar, A Zupanic, p. 630. Berlin: Springer
130. Reed SD, Fulmer A, Buckholz J, Zhang B, Cutrera J, et al. 2010. Bleomycin/interleukin-12 electrochemo-genetherapy for treating naturally occurring spontaneous neoplasmsindogs.Cancer Gene Ther.17:571-78
131. Nomura M, Nakata Y, Inoue T, Uzawa A, Itamura S, et al. 1996. In vivo induction of cytotoxic T lymphocytes specific for a single epitope introduced into an unrelated molecule. J. Immunol. Methods 193:41-49
132. Van Drunen Littel-Van den Hurk S, Hannaman D. 2010. Electroporation for DNA immunization: clinical application. Expert Rev. Vaccines 9:503-17
133. Livingston BD, Little SF, Luxembourg A, Ellefsen B, Hannaman D. 2010. Comparative performance of a licensed anthrax vaccine versus electroporation based delivery of a PA encoding DNA vaccine in rhesus macaques. Vaccine 28:1056-61
134. Best SR, Peng S, Juang CM, Hung CF, Hannaman D, et al. 2009. Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery. Vaccine 27:5450-59
135. Rosati M, Valentin A, Jalah R, Patel V, Von Gegerfelt A, et al. 2008. Increased immune responses in rhesus macaques by DNA vaccination combined with electroporation. Vaccine 26:5223-29
136. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, Le Deist F, Wulffraat N, et al. 2003. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 348:255-56
137. Ribeiro S, Mairhofer J, Madeira C, Diogo MM, Lobato da Silva C, et al. 2012. Plasmid DNA size does affect nonviral gene delivery efficiency in stem cells. Cell. Reprogram. 14:130-37
138. Epsztejn-Litman S, Eiges R. 2010. Genetic manipulation of human embryonic stem cells. In Human Embryonic Stem Cell Protocols, ed. K Turksen, pp. 387-411. New York: Humana
139. Fernand F, Rubinsky L, Golberg A, Rubinsky B. 2012. Variable electric fields for high throughput electroporation protocol design in curvilinear coordinates. Biotechnol. Bioeng. 109:2168-71
140. Shengnian W, Lee LJ. 2013. Micro-/nanofluidics based cell electroporation. Biomicrofluidics 7:011301
141. Huang Y, Rubinsky B. 2001. Microfabricated electroporation chip for single cell membrane permeabi-lization. Sens. Actuators A Phys. 89:242-49
142. Geng T, Zhan Y, Wang HY, Witting SR, Cornetta KG, Lu C. 2010. Flow-through electroporation based on constant voltage for large-volume transfection of cells. J. Control. Release 144:91-100
143. Zorec B, Préat V, Miklavčič D, Pavšelj N. 2013. Active enhancement methods for intra-and transdermal drug delivery: a review. Slovenian Med. J. 82:339-56
144. Denet A-R, Vanbever R, Préat V. 2004. Skin electroporation for transdermal and topical delivery. Adv. Drug Deliv. Rev. 56:659-74
145. Prausnitz MR, Langer R. 2008. Transdermal drug delivery. Nat. Biotechnol. 26:1261-68
146. Pavšelj N, Préat V, Miklavčič D. 2007. A numerical model of skin electropermeabilization based on in vivo experiments. Ann. Biomed. Eng. 35:2138-44
147. Pliquett U, Weaver JC. 2007. Feasibility of an electrode-reservoir device for transdermal drug delivery by noninvasive skin electroporation. IEEE Trans. Biomed. Eng. 54:536-38
148. Pavšelj N, Miklavčič D. 2008. A numerical model of permeabilized skin with local transport regions. IEEE Trans. Biomed. Eng. 55:1927-30
149. Vanbever R, LeBoulenge E, Préat V. 1996. Transdermal delivery of fentanyl by electroporation. I. Influence of electrical factors. Pharm. Res. 4:559-65
150. Wong TW, Chen TY, Huang CC, Tsai JC, Hui SW. 2011. Painless skin electroporation as a novel way for insulin delivery. Diabetes Technol. Ther. 13:929-35
151. Blagus T, Markelc B, Cemažar M, Kosjek T, Préat V, et al. 2013. In vivo real-time monitoring system of electroporation mediated control of transdermal and topical drug delivery. J. Control. Release 172:862-71
152. Regnier V, DeMorre N, Jadoul A, Préat V. 1999. Mechanisms of a phosphorothioate oligonucleotide delivery by skin electroporation. Int. J. Pharm. 184:147-56
153. Dujardin N, Van Deŕ Smissen P, Préat V. 2001. Topical gene transfer into rat skin using electroporation. Pharm. Res. 1:61-66
154. Pavšelj N, Préat V. 2005. DNA electrotransfer into the skin using a combination of one high-and one low-voltage pulse. J. Control. Release 106:407-15
155. Zhao YL, Murthy SN, Manjili MH, Guan LJ, Sen A, Hui SW. 2006. Induction of cytotoxic T-lymphocytes by electroporation-enhanced needle-free skin immunization. Vaccine 24:1282-90
156. Kang TH, Monie A, Wu LSF, Pang X, Hung C-F, Wu TC. 2011. Enhancement of protein vaccine potency by in vivo electroporation mediated intramuscular injection. Vaccine 29:1082-89
157. Edd JF, Davalos RV. 2007. Mathematical modeling of irreversible electroporation for treatment planning. Technol. Cancer Res. Treat. 6:275-86
158. Zupanic A, Kos B, Miklavčič D. 2012. Treatment planning of electroporation-based medical interventions: electrochemotherapy, gene electrotransfer and irreversible electroporation. Phys. Med. Biol. 57:5425-40
159. Garcia PA, Rossmeisl JH, Neal RE, Ellis TL, Olson JD, et al. 2010. Intracranial nonthermal irreversible electroporation: in vivo analysis. J. Membr. Biol. 236:127-36
160. Appelbaum L, Ben-David E, Sosna J, Nissenbaum Y, Goldberg SN. 2012. US findings after irreversible electroporation ablation: radiologic-pathologic correlation. Radiology 262:117-25
161. Wendler JJ, Pech M, Porsch M, Janitzky A, Fischbach F, et al. 2012. Urinary tract effects after multi-focal nonthermal irreversible electroporation of the kidney: acute and chronic monitoring by magnetic resonance imaging, intravenous urography and urinary cytology. Cardiovasc. Interv. Radiol. 35:921-26
162. Calmels L, Al-Sakere B, Ruaud J-P, Leroy-Willig A, Mir LM. 2012. In vivo MRI follow-up of murine tumors treated by electrochemotherapy and other electroporation-based treatments. Technol. Cancer Res. Treat. 11:561-70
163. Hjouj M, Last D, Guez D, Daniels D, Sharabi S, et al. 2012. MRI study on reversible and irreversible electroporation induced blood brain barrier disruption. PLoS ONE 7:e42817
164. Corovic S, Zupanic A, Kranjc S, Al Sakere B, Leroy-Willig A, et al. 2010. The influence of skeletal muscle anisotropy on electroporation: in vivo study and numerical modeling. Med. Biol. Eng. Comput. 48:637-48
165. Neal R II, Cheung W, Kavnoudias H, Thomson K. 2012. Spectrum of imaging and characteristics for liver tumors treated with irreversible electroporation. J. Biomed. Sci. Eng. 5:813-18
166. Mozzillo N, Caraco C, Mori S, Di Monta G, Botti G, et al. 2012. Use of neoadjuvant electrochemotherapy to treat a large metastatic lesion of the cheek in a patient with melanoma. J. Transl. Med. 10:131
167. Cukjati D, Batiuskaite D, André F, Miklavčič D, Mir LM. 2007. Real time electroporation control for accurate and safe in vivo non-viral gene therapy. Bioelectrochemistry 70:501-7
168. Golberg A, Laufer S, Rabinowitch HD, Rubinsky B. 2011. In vivo non-thermal irreversible electropo-ration impact on rat liver galvanic apparent internal resistance. Phys. Med. Biol. 56:951-63
169. Granot Y, Ivorra A, Maor E, Rubinsky B. 2009. In vivo imaging of irreversible electroporation by means of electrical impedance tomography. Phys. Med. Biol. 54:4927-43
170. Ivorra A, Al-Sakere B, Rubinsky B, Mir LM. 2009. In vivo electrical conductivity measurements during and after tumor electroporation: Conductivity changes reflect the treatment outcome. Phys. Med. Biol. 54:5949-63
171. Golberg A, Rabinowitch HD, Rubinsky B. 2009. Galvanic apparent internal impedance: an intrinsic tissue property. Biochem. Biophys. Res. Commun. 389:168-71
172. Granot Y, Rubinsky B. 2007. Methods of optimization of electrical impedance tomography for imaging tissue electroporation. Physiol. Meas. 28:1135-47
173. Kranjc M, Bajd F, Serša I, Miklavčič D. 2011. Magnetic resonance electrical impedance tomography for monitoring electric field distribution during tissue electroporation. IEEE Trans. Med. Imaging 30:1771-78
174. Kranjc M, Bajd F, Serša I, Woo EJ, Miklavčič D. 2012. Ex vivo and in silico feasibility study of monitoring electric field distribution in tissue during electroporation based treatments. PLoS ONE 7:e45737
175. Pavliha D, Kos B, Marcan M, Zupanic A, Serša G, Miklavčič D. 2013. Planning of electroporation-based treatments using web-based treatment-planning software. J. Membr. Biol. 246:833-42
176. Arena CB, Sano MB, Rossmeisl JH, Caldwell JL, Garcia PA, et al. 2011. High-frequency irreversible electroporation (H-FIRE) for non-thermal ablation without muscle contraction. Biomed. Eng. OnLine 10:102
177. Golberg A, Rubinsky B. 2012. Towards electroporation based treatment planning considering electric field induced muscle contractions. Technol. Cancer Res. Treat. 11:189-201
178. Sano M, Neal R, Garcia P, Gerber D, Robertson J, Davalos R. 2010. Towards the creation of decellu-larized organ constructs using irreversible electroporation and active mechanical perfusion. Biomed. Eng. OnLine 9:83
179. Markelc B, Tevž G, Cemažar M, Kranjc S, Lavrenčak J, et al. 2012. Muscle gene electrotransfer is increased by the antioxidant tempol in mice. Gene Ther. 19:312-20
180. Cemažar M, Golzio M, Serša G, Escoffre JM, Coer A, et al. 2012. Hyaluronidase and collagenase increase the transfection efficiency of gene electrotransfer in various murine tumors. Hum. Gene Ther. 23:128-37
181. Kotnik T. 2013. Lightning-triggered electroporation and electrofusion as possible contributors to natural horizontal gene transfer. Phys. Life Rev. 10:351-70
182. Dev SB, Rabussay DP, Widera G, Hofmann GA. 2000. Medical applications of electroporation. IEEE Trans. Plasma Sci. 28:206-23
183. Bower M, Sherwood L, Li Y, Martin R. 2011. Irreversible electroporation of the pancreas: definitive local therapy without systemic effects. J. Surg. Oncol. 104:22-28
184. Zorec B, Miklavčič D, Jelenc J, Pavšelj N. 2013. Enhanced transport of Patent Blue dye through the stratum corneum using Green Skin Pore electroporator. J. Laser Health Acad. 1:S30